Compare Cassava Sciences Inc (FLNA) vs Morgan Stanley (MS) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Morgan Stanley (MS) trades at $228.17, up 3.2% with strong technical and fundamental momentum. The stock shows bullish technical signals with consistent earnings beats and robust revenue growth from $57.6B in 2024 to $66.0B in 2025. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management, reinforcing its market position.

Outlook remains positive with analyst consensus at Buy (53.85%) and $229 price target. Key opportunities include sustained earnings growth and strategic initiatives, while risks involve volatile cash flows and high debt levels. The stock presents a balanced risk-reward profile for investors seeking financial sector exposure.